Bipolar DisorderFACSNCT04716036
Familial Risk for Bipolar Disorder and Alcohol Sensitivity
A study testing Alcohol beverage in people with Bipolar Disorder and Alcohol Drinking, run by University of Texas at Austin at 1 site in United States.
Trial summary
Early identification in individuals with bipolar disorder who are at risk for AUDs could inform novel intervention strategies and improve life-long outcomes. The primary objective of this protocol is to use alcohol administration procedures and alcohol biosensor technology to investigate responses to alcohol, compared… Read more about this study
- Who is it for?
- Ages 21 to 26 yearsHealthy volunteers can take part
- Conditions the study is for
- Bipolar Disorder, Alcohol Drinking, Alcohol Use Disorder
- What is being tested?
- Alcohol beverage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 68 participants
- Where
- 1 siteUnited States
- Study dates
- 13 May 2021to 30 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 26 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- between 21 and 26 years of age
- having consumed at least 4 (men) or 3 (women) drinks on a single occasion at least twice over the last year
- euthymic at the time of study
- Inclusion criteria for familial risk for bipolar disorder (only) participants:
- having at least one parent diagnosed with bipolar disorder type I, confirmed by family history interview
- Inclusion criteria for familial risk for both bipolar disorder and alcohol use disorders participants:
Show all 10Show fewer
- having at least one parent diagnosed with bipolar disorder type I, confirmed by family history interview
- having at least one parent diagnosed with an alcohol use disorder, confirmed by family history interview
- Inclusion criteria for familial risk for alcohol use disorders (only) participants:
- having at least one parent diagnosed with an alcohol use disorder, confirmed by family history interview
Who cannot join
- For all subjects exclusion criteria include:
- history of manic episode
- history of psychosis
- history of significant medical illness, particularly if possible changes in cerebral tissue
- full Scale IQ <85
- positive pregnancy test
Show all 25Show fewer
- history of cannabis use disorder>moderate over past year
- history of AUD>mild over lifetime
- scores > 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone screen)
- ever being in an abstinence-oriented treatment program for alcohol use
- reporting wanting to quit drinking but not being able to
- any medical, religious, or other reasons for not drinking alcohol
- history of heart attack, heart trouble, high blood pressure, diabetes, or liver disease
- an adverse reaction to alcoholic beverages
- a flushing response (possibly suggesting altered alcohol metabolism)
- reporting never consuming 4 (men) or 3 (women) or more drinks on a single occasion at least twice over the last year
- unwillingness to have a friend or family member drive them home after the alcohol administration sessions
- a past substance use disorder (other than alcohol, cannabis, or nicotine) over the past year
- Additional exclusion criteria for familial risk for bipolar disorder participants:
- not taking medications for >4 weeks (i.e. participants must be stable on antidepressant or anti-anxiety medication)
- Additional exclusion criteria for healthy comparison subjects also include:
- any prior psychiatric hospitalizations
- lifetime history of a neurodevelopmental disorder, affective disorder, psychotic disorder, eating disorder
- having a parent diagnosed with a mood disorder or AUD
- greater than 1 month of lifetime psychotropic medication
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Dissecting Responses to Alcohol in Individuals With Familial Risk for Bipolar Disorder
Early identification in individuals with bipolar disorder who are at risk for AUDs could inform novel intervention strategies and improve life-long outcomes. The primary objective of this protocol is to use alcohol administration procedures and alcohol biosensor technology to investigate responses to alcohol, compared to placebo, and relationship with parental risk for alcohol use disorders and/or bipolar disorder in young adults. Baseline clinical, cognitive, and behavioral assessments will be completed in 100 young adults (21-26 years; 50% women, no history of AUDs>mild). Participants would be equally divided among those with parental history of bipolar disorder but not AUDs, parental history of bipolar disorder and AUDs, parental history of AUDs but not bipolar disorder, and typically developing age- and sex-matched controls with no parental history of mood disorders or AUDs (N=25 per group). Then, while wearing Secure Continuous Remote Alcohol Monitoring [SCRAM] sensors, participants will complete within-person, counter-balanced, beverage sessions (following standard beverage administration procedures) in a simulated bar laboratory. Changes in heart rate, body sway and subjective self-report measurements of intoxication will also be completed while under the influence of alcohol or placebo. Specifically, individual differences in transdermal alcohol concentration (the primary data output from SCRAM sensors), physiological changes (e.g. heart rate), and the experience of stimulating, sedative, and anxiolytic effects of alcohol (measured with self-report surveys) will be investigated and differences between parental risk subgroups and healthy comparison participants investigated. Differences in transdermal alcohol concentration collected while under the influence of alcohol will be the primary data outcome assessed. Changes in heart rate, body sway, and experience of stimulating, sedative, and anxiolytic effects (from self-report survey data) while under the influence of alcohol compared to placebo session will also be investigated. Additionally, associations between objective and subjective responses to alcohol and drinking patterns will be explored (secondary outcome). The primary endpoint of the study will be after completion of both alcohol and placebo beverage conditions.
Read the detailed description
A total of 100 young adults (21-26 years; 50% women, no history of AUDs>mild) will be recruited from the greater Austin area. Participants will be equally divided among those with parental history of bipolar disorder but not AUDs, parental history of bipolar disorder and AUDs, parental history of AUDs but not bipolar disorder, and typically developing age- and sex-matched controls with no parental history of mood disorders or AUDs (N=25 per group). The phone screen used for this study will assess parental history and clinical symptoms to achieve these recruitment goals for each subgroup.
Once recruited and enrolled, subjects will undergo detailed structured clinical evaluations to verify inclusion and exclusion criteria (including family history), comprehensive assessment of alcohol and other drug use history, and cognitive testing. Participants will return to the laboratory on subsequent days and complete their alcohol/placebo sessions while wearing Secure Continuous Remote Alcohol Monitoring (SCRAM) sensors and under the influence of alcohol or a placebo condition (counter-balanced). Following standard beverage administration procedures in a simulated bar laboratory, changes in heart rate, body sway, and self-report measures of subjective response to alcohol will be measured. Up to four participants will complete the beverage session together in the bar laboratory. This increases the ecological validity and strengthens the placebo manipulation. It also increases subject flow. Participants will be escorted to a private assessment room for all behavioral assessments. For each participant the first beverage session assignment (whether the participant is given alcohol or the placebo beverage first) will be randomized. The SCRAM sensor will be worn continuously and measure transdermal alcohol concentration throughout the alcohol and placebo sessions. Participants will wear the SCRAM sensor home overnight following their alcohol session and return the next morning for SCRAM sensor removal. Transdermal alcohol concentration is continuously collected overnight following an alcohol session. Participants will not be required to wear the SCRAM sensor home after their placebo session. For the placebo session, we will inform participants they received a low dose of alcohol and that their BrAC is at 0.0g% at the end of the session so monitoring overnight is not needed. Alcohol and placebo sessions will occur within 3 days of each other.
For both the alcohol and the placebo beverage conditions, the protocol will be the same. The beverage administration sessions will in a simulated bar laboratory in co-Investigator, Kim Fromme's, research suite at the University of Texas at Austin. The table in the testing room will be wiped down with alcohol prior to the participant's arrival (olfactory cue). Study staff will use an algorithm to calculate individual alcohol doses based on the participants' age, sex, height, and weight. Participants fast from food for 4 hours prior to their session. Before beginning consumption of their beverages, they will eat a weight-adjusted, 1 calorie per pound snack of pretzels. While participants eat their pretzels, study staff will mix beverages in front of participants. Vodka and placebo (decarbonated tonic water) will be stored in absolute vodka bottles, measured out, and combined with mixer in front of participants. Mixed drinks will be poured into glasses that have been sitting face down with rims soaking in vodka. Prior to giving the beverage to the participant, all drinks will get an alcohol floater (squirt of absolute vodka on top of the drink). Participants will be given 20 minutes to orally consume two beverages (10 minutes per beverage).
Following oral consumption and a 15-minute absorption period, breathalyzer tests will be conducted every 10 minutes to identify a .06g% ascending limb breath alcohol concentration (BrAC). Heart rate, body sway, and self-report of response to alcohol will be collected. BrAC will be measured at approximate 10 minute intervals, and heart rate, body sway, and subjective response to alcohol collected again at peak BrAC (0.08g%) and at descending BrAC of .06g%. Baseline heart rate, body sway, and self-report response (with instructions modified to ask how participants feel when they first arrive to the laboratory) are also collected before sessions begin so change on test days (e.g. peak 0.08g% BrAC heart rate - baseline heart rate) is calculated. Consistent with NIAAA guidelines for human alcohol studies, BrAC readings will continue every 30 minutes until participants are below 0.04% at which time they are escorted home. During the placebo condition, participants are told they will receive varying doses of alcohol, provided ambient olfactory cues, the rims of glasses are soaked in vodka, and alcohol floater is added to beverages (gustatory cues). A placebo manipulation test is measured during the ascending limb (placebo: after the absorption period with time of test given at the average time it takes individuals to reach ascending 0.06g% BrAC during the alcohol session) and when participants reach ascending 0.06g% BrAC (during alcohol session). Participants are asked to estimate the number of standard alcoholic drinks they were served. The average time participants stay in the laboratory will be shorter for the placebo vs. alcohol beverage condition. Participants are told they received a lower dose of alcohol and at the end of the placebo session they are told their BrAC is 0.0g%. They therefore do not need to wear the SCRAM sensor home. During the alcohol session participants are released at 0.04g% and they are told they need to wear the SCRAM sensor home overnight. Participants are debriefed, including BrAC reached during sessions, after they complete both sessions.
- Conditions
- Bipolar Disorder, Alcohol Drinking, Alcohol Use Disorder
- Being tested
- Alcohol beverage, Placebo beverage
- Medical subject headings
- Bipolar Disorder, Alcohol Drinking, Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alcohol beverageOther
Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
Placebo beverageOther
placebo beverage condition.
| Study group | Role | What they receive |
|---|---|---|
| Alcohol | Active comparator | Participants will be dosed to a 0.08g% blood alcohol concentration. Receives: Other: Alcohol beverage |
| Placebo | Placebo comparator | Participants will receive a low dose of alcohol (placebo condition). Receives: Other: Placebo beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in transdermal alcohol concentration: time to peak TAC
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. time to reach peak TAC [measured in minutes]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
Measured: up to 24 hours
Changes in transdermal alcohol concentration: peak TAC experienced
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. peak TAC [g/dL]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
Measured: up to 24 hours
Changes in transdermal alcohol concentration: area under the curve (AUC)
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. geometric area under the curve [AUC]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
The units of the AUC are the units of the Y axis times units of the X axis. Y axis measures transdermal alcohol concentration in g/dL and the X axis measures time in minutes. The area is therefore expressed in units of (g/dL) x minutes.
Measured: up to 24 hours
Changes in transdermal alcohol concentration: absorption and elimination rates (g/dL per hour)
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. absorption and elimination rates[g/dL per hour]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
Absorption rate is calculated as peak TAC (g/dL) divided by the time it took to rise from .000 to the peak; elimination rate is calculated as peak TAC divided by the time it took to decline from peak to .000 again.
Measured: up to 24 hours
Change (peak BrAC minus baseline BrAC) in heart rate will be compared between alcohol and placebo sessions.
Participants will have heart rate (beats per minute) measured they first arrive to both beverage administration sessions (alcohol and placebo). They will then have heart rate collected again during their beverage sessions (alcohol and placebo) at target BrACs (i.e, .08g%). Changes in heart rate will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
Measured: up to 6 hours for alcohol session and up to 6 hours for placebo session
Change (peak BrAC minus baseline BrAC) in body sway will be compared between alcohol and placebo sessions.
Participants will body sway measured when they first arrive to both beverage administration sessions (alcohol and placebo). They will then have body sway measured during their beverage sessions (alcohol and placebo) at target BrAC (.08g%). Changes in body sway will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
Measured: up to 6 hours for alcohol session and up to 6 hours for placebo session
Change (peak BrAC minus baseline BrAC) in behavior (self-report surveys) will be compared between alcohol and placebo sessions.
Participants will fill out self-report surveys (i.e., subjective effects of alcohol scale, drug effects questionnaire) on how they feel when they first arrive to both beverage administration sessions (alcohol and placebo). They will then fill out the same self-report surveys on how intoxicated they feel during their beverage sessions (alcohol and placebo) at target BrACs (i.e., .08g%). Changes in how intoxicated they feel will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
Measured: up to 6 hours for alcohol session and up to 6 hours for placebo session
Secondary outcomes (4)
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: time to reach peak TAC
Participants will complete a structured assessment (time line follow back) to assess recent alcohol use including quantity (total drinks, average drinks per drinking day). Correlations between recent alcohol use and transdermal alcohol data (i.e. time to reach peak TAC [measured in minutes]) will be explored.
Measured: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: peak TAC
Participants will complete a structured assessment (time line follow back) to assess recent alcohol use including quantity (total drinks, average drinks per drinking day). Correlations between recent alcohol use and transdermal alcohol data (i.e. peak TAC [g/dL]) will be explored.
Measured: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: area under the curve (AUC)
Participants will complete a structured assessment (time line follow back) to assess recent alcohol use including quantity (total drinks, average drinks per drinking day). Correlations between recent alcohol use and transdermal alcohol data (i.e. geometric area under the curve [(g/dL) x minutes]) will be explored.
The units of the AUC are the units of the Y axis times units of the X axis. Y axis measures transdermal alcohol concentration in g/dL and the X axis measures time in minutes. The area is therefore expressed in units of (g/dL) x minutes.
Measured: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: absorption and elimination rates
Participants will complete a structured assessment (time line follow back) to assess recent alcohol use including quantity (total drinks, average drinks per drinking day). Correlations between recent alcohol use and transdermal alcohol data (i.e. absorption and elimination rates [g/dL per hour]) will be explored.
Absorption rate is calculated as peak TAC (g/dL) divided by the time it took to rise from .000 to the peak; elimination rate is calculated as peak TAC divided by the time it took to decline from peak to .000 again.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2021
- Study start13 May 2021
- Primary completion30 Apr 2024
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bipolar DisorderStudies of the same condition, open and under way.
- More trials run by University of Texas at AustinThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Texas at Austin
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elizabeth Thomas Cox Lippard, University of Texas at Austin
- Investigators
- Elizabeth Lippard, PhD, Principal investigator, University of Texas at Austin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04716036
- Sponsor's protocol ID
- R21AA027884
- Acronym
- FACS
- Status last verified
- Jul 2024
- First submitted
- 12 Jan 2021
- Last updated
- 24 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After study completion and publication of finding, transdermal alcohol concentration data and behavioral data collected following alcohol and placebo conditions will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dissecting Responses to Alcohol in Individuals With Familial Risk for Bipolar Disorder
- ClinicalTrials.gov ID
- NCT04716036
- Acronym / sponsor ID
- FACS / R21AA027884
- Conditions
- Bipolar Disorder, Alcohol Drinking, Alcohol Use Disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- University of Texas at AustinUniversity, hospital or other
- Study start
- 13 May 2021 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 20 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Early identification in individuals with bipolar disorder who are at risk for AUDs could inform novel intervention strategies and improve life-long outcomes. The primary objective of this protocol is to use alcohol administration procedures and alcohol biosensor technology to investigate responses to alcohol, compared to placebo, and relationship with parental risk for alcohol use disorders and/or bipolar disorder in young adults. Baseline clinical, cognitive, and behavioral assessments will be completed in 100 young adults (21-26 years; 50% women, no history of AUDs>mild). Participants would be equally divided among those with parental history of bipolar disorder but not AUDs, parental history of bipolar disorder and AUDs, parental history of AUDs but not bipolar disorder, and typically developing age- and sex-matched controls with no parental history of mood disorders or AUDs (N=25 per group). Then, while wearing Secure Continuous Remote Alcohol Monitoring [SCRAM] sensors, participants will complete within-person, counter-balanced, beverage sessions (following standard beverage administration procedures) in a simulated bar laboratory. Changes in heart rate, body sway and subjective self-report measurements of intoxication will also be completed while under the influence of alcohol or placebo. Specifically, individual differences in transdermal alcohol concentration (the primary data output from SCRAM sensors), physiological changes (e.g. heart rate), and the experience of stimulating, sedative, and anxiolytic effects of alcohol (measured with self-report surveys) will be investigated and differences between parental risk subgroups and healthy comparison participants investigated. Differences in transdermal alcohol concentration collected while under the influence of alcohol will be the primary data outcome assessed. Changes in heart rate, body sway, and experience of stimulating, sedative, and anxiolytic effects (from self-report survey data) while under the influence of alcohol compared to placebo session will also be investigated. Additionally, associations between objective and subjective responses to alcohol and drinking patterns will be explored (secondary outcome). The primary endpoint of the study will be after completion of both alcohol and placebo beverage conditions.
Detailed description
A total of 100 young adults (21-26 years; 50% women, no history of AUDs>mild) will be recruited from the greater Austin area. Participants will be equally divided among those with parental history of bipolar disorder but not AUDs, parental history of bipolar disorder and AUDs, parental history of AUDs but not bipolar disorder, and typically developing age- and sex-matched controls with no parental history of mood disorders or AUDs (N=25 per group). The phone screen used for this study will assess parental history and clinical symptoms to achieve these recruitment goals for each subgroup.
Once recruited and enrolled, subjects will undergo detailed structured clinical evaluations to verify inclusion and exclusion criteria (including family history), comprehensive assessment of alcohol and other drug use history, and cognitive testing. Participants will return to the laboratory on subsequent days and complete their alcohol/placebo sessions while wearing Secure Continuous Remote Alcohol Monitoring (SCRAM) sensors and under the influence of alcohol or a placebo condition (counter-balanced). Following standard beverage administration procedures in a simulated bar laboratory, changes in heart rate, body sway, and self-report measures of subjective response to alcohol will be measured. Up to four participants will complete the beverage session together in the bar laboratory. This increases the ecological validity and strengthens the placebo manipulation. It also increases subject flow. Participants will be escorted to a private assessment room for all behavioral assessments. For each participant the first beverage session assignment (whether the participant is given alcohol or the placebo beverage first) will be randomized. The SCRAM sensor will be worn continuously and measure transdermal alcohol concentration throughout the alcohol and placebo sessions. Participants will wear the SCRAM sensor home overnight following their alcohol session and return the next morning for SCRAM sensor removal. Transdermal alcohol concentration is continuously collected overnight following an alcohol session. Participants will not be required to wear the SCRAM sensor home after their placebo session. For the placebo session, we will inform participants they received a low dose of alcohol and that their BrAC is at 0.0g% at the end of the session so monitoring overnight is not needed. Alcohol and placebo sessions will occur within 3 days of each other.
For both the alcohol and the placebo beverage conditions, the protocol will be the same. The beverage administration sessions will in a simulated bar laboratory in co-Investigator, Kim Fromme's, research suite at the University of Texas at Austin. The table in the testing room will be wiped down with alcohol prior to the participant's arrival (olfactory cue). Study staff will use an algorithm to calculate individual alcohol doses based on the participants' age, sex, height, and weight. Participants fast from food for 4 hours prior to their session. Before beginning consumption of their beverages, they will eat a weight-adjusted, 1 calorie per pound snack of pretzels. While participants eat their pretzels, study staff will mix beverages in front of participants. Vodka and placebo (decarbonated tonic water) will be stored in absolute vodka bottles, measured out, and combined with mixer in front of participants. Mixed drinks will be poured into glasses that have been sitting face down with rims soaking in vodka. Prior to giving the beverage to the participant, all drinks will get an alcohol floater (squirt of absolute vodka on top of the drink). Participants will be given 20 minutes to orally consume two beverages (10 minutes per beverage).
Following oral consumption and a 15-minute absorption period, breathalyzer tests will be conducted every 10 minutes to identify a .06g% ascending limb breath alcohol concentration (BrAC). Heart rate, body sway, and self-report of response to alcohol will be collected. BrAC will be measured at approximate 10 minute intervals, and heart rate, body sway, and subjective response to alcohol collected again at peak BrAC (0.08g%) and at descending BrAC of .06g%. Baseline heart rate, body sway, and self-report response (with instructions modified to ask how participants feel when they first arrive to the laboratory) are also collected before sessions begin so change on test days (e.g. peak 0.08g% BrAC heart rate - baseline heart rate) is calculated. Consistent with NIAAA guidelines for human alcohol studies, BrAC readings will continue every 30 minutes until participants are below 0.04% at which time they are escorted home. During the placebo condition, participants are told they will receive varying doses of alcohol, provided ambient olfactory cues, the rims of glasses are soaked in vodka, and alcohol floater is added to beverages (gustatory cues). A placebo manipulation test is measured during the ascending limb (placebo: after the absorption period with time of test given at the average time it takes individuals to reach ascending 0.06g% BrAC during the alcohol session) and when participants reach ascending 0.06g% BrAC (during alcohol session). Participants are asked to estimate the number of standard alcoholic drinks they were served. The average time participants stay in the laboratory will be shorter for the placebo vs. alcohol beverage condition. Participants are told they received a lower dose of alcohol and at the end of the placebo session they are told their BrAC is 0.0g%. They therefore do not need to wear the SCRAM sensor home. During the alcohol session participants are released at 0.04g% and they are told they need to wear the SCRAM sensor home overnight. Participants are debriefed, including BrAC reached during sessions, after they complete both sessions.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Alcohol | Active comparator | Other: Alcohol beverageParticipants will be dosed to a 0.08g% blood alcohol concentration. |
| Placebo | Placebo comparator | Other: Placebo beverageParticipants will receive a low dose of alcohol (placebo condition). |
Who may qualify
- Ages
- 21 to 26 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- between 21 and 26 years of age
- having consumed at least 4 (men) or 3 (women) drinks on a single occasion at least twice over the last year
- euthymic at the time of study
- having at least one parent diagnosed with bipolar disorder type I, confirmed by family history interview
- Inclusion criteria for familial risk for both bipolar disorder and alcohol use disorders participants:
Key exclusion criteria (25 listed)
- history of manic episode
- history of psychosis
- history of significant medical illness, particularly if possible changes in cerebral tissue
- full Scale IQ <85
- positive pregnancy test
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alcohol beverageParticipants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined. | Other | Alcohol |
| Placebo beverageplacebo beverage condition. | Other | Placebo |
Primary outcome
Changes in transdermal alcohol concentration: time to peak TAC
Time frame: up to 24 hours
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. time to reach peak TAC [measured in minutes]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
Changes in transdermal alcohol concentration: peak TAC experienced
Time frame: up to 24 hours
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. peak TAC [g/dL]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes).
Changes in transdermal alcohol concentration: area under the curve (AUC)
Time frame: up to 24 hours
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. geometric area under the curve [AUC]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes). The units of the AUC are the units of the Y axis times units of the X axis. Y axis measures transdermal alcohol concentration in g/dL and the X axis measures time in minutes. The area is therefore expressed in units of (g/dL) x minutes.
Changes in transdermal alcohol concentration: absorption and elimination rates (g/dL per hour)
Time frame: up to 24 hours
Changes in transdermal alcohol concentration (TAC) during the alcohol session (i.e. absorption and elimination rates[g/dL per hour]) will be compared between subgroups. Study participation to collect data (baseline clinical assessment, alcohol and placebo beverage sessions) should not take more than 13 hours. Participants will wear SCRAM sensors overnight following their alcohol session and return the following morning for SCRAM sensor removal (which takes <15 minutes). Absorption rate is calculated as peak TAC (g/dL) divided by the time it took to rise from .000 to the peak; elimination rate is calculated as peak TAC divided by the time it took to decline from peak to .000 again.
Change (peak BrAC minus baseline BrAC) in heart rate will be compared between alcohol and placebo sessions.
Time frame: up to 6 hours for alcohol session and up to 6 hours for placebo session
Participants will have heart rate (beats per minute) measured they first arrive to both beverage administration sessions (alcohol and placebo). They will then have heart rate collected again during their beverage sessions (alcohol and placebo) at target BrACs (i.e, .08g%). Changes in heart rate will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
Change (peak BrAC minus baseline BrAC) in body sway will be compared between alcohol and placebo sessions.
Time frame: up to 6 hours for alcohol session and up to 6 hours for placebo session
Participants will body sway measured when they first arrive to both beverage administration sessions (alcohol and placebo). They will then have body sway measured during their beverage sessions (alcohol and placebo) at target BrAC (.08g%). Changes in body sway will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
Change (peak BrAC minus baseline BrAC) in behavior (self-report surveys) will be compared between alcohol and placebo sessions.
Time frame: up to 6 hours for alcohol session and up to 6 hours for placebo session
Participants will fill out self-report surveys (i.e., subjective effects of alcohol scale, drug effects questionnaire) on how they feel when they first arrive to both beverage administration sessions (alcohol and placebo). They will then fill out the same self-report surveys on how intoxicated they feel during their beverage sessions (alcohol and placebo) at target BrACs (i.e., .08g%). Changes in how intoxicated they feel will be calculated for both the alcohol and placebo conditions (i.e. at peak BrAC minus baseline BrAC) and compared.
4 secondary outcomes
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: time to reach peak TAC
Time frame: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: peak TAC
Time frame: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: area under the curve (AUC)
Time frame: baseline
Recent alcohol use patterns relations with variability in transdermal alcohol concentration: absorption and elimination rates
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2024.
- Individual participant dataSharing planned: Yes. After study completion and publication of finding, transdermal alcohol concentration data and behavioral data collected following alcohol and placebo conditions will be shared.
Related trials for Bipolar Disorder
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Recruiting
Safety and Feasibility of DBS for Bipolar Depression
Bipolar I Disorder, Bipolar Depression
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Recruiting
Affective Cognitive Training in Mood Disorders and High-risk Relatives
Major Depressive Disorder (MDD), Bipolar Disorder (BD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elizabeth Lippard, PhD principal investigator
University of Texas at Austin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alcohol beverage in people with Bipolar Disorder and Alcohol Drinking, run by University of Texas at Austin at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in transdermal alcohol concentration: time to peak TAC (time frame: up to 24 hours). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2024.